PL1624878T3 - Zastosowanie kompozycji zawierającej estrogenowy składnik w celu leczenia i zapobiegania bólowi mięśniowo-szkieletowemu - Google Patents

Zastosowanie kompozycji zawierającej estrogenowy składnik w celu leczenia i zapobiegania bólowi mięśniowo-szkieletowemu

Info

Publication number
PL1624878T3
PL1624878T3 PL04734005T PL04734005T PL1624878T3 PL 1624878 T3 PL1624878 T3 PL 1624878T3 PL 04734005 T PL04734005 T PL 04734005T PL 04734005 T PL04734005 T PL 04734005T PL 1624878 T3 PL1624878 T3 PL 1624878T3
Authority
PL
Poland
Prior art keywords
sub
estrogenic component
group
inhibitors
musculoskeletal pain
Prior art date
Application number
PL04734005T
Other languages
English (en)
Inventor
Bennink Herman Jan Tijmen Coelingh
Evert Johannes Bunschoten
Original Assignee
Pantarhei Bioscience Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv
Publication of PL1624878T3 publication Critical patent/PL1624878T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL04734005T 2003-05-22 2004-05-19 Zastosowanie kompozycji zawierającej estrogenowy składnik w celu leczenia i zapobiegania bólowi mięśniowo-szkieletowemu PL1624878T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03076555 2003-05-22
PCT/NL2004/000354 WO2004103377A1 (en) 2003-05-22 2004-05-19 Use of compositions comprising an estrogenic component for the treatment and prevention of musculoskeletal pain
EP04734005A EP1624878B1 (en) 2003-05-22 2004-05-19 Use of compositions comprising an estrogenic component for the treatment and prevention of musculoskeletal pain

Publications (1)

Publication Number Publication Date
PL1624878T3 true PL1624878T3 (pl) 2007-01-31

Family

ID=33462160

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04734005T PL1624878T3 (pl) 2003-05-22 2004-05-19 Zastosowanie kompozycji zawierającej estrogenowy składnik w celu leczenia i zapobiegania bólowi mięśniowo-szkieletowemu

Country Status (13)

Country Link
US (1) US20060276414A1 (pl)
EP (1) EP1624878B1 (pl)
CN (1) CN100431545C (pl)
AT (1) ATE340580T1 (pl)
CA (1) CA2526338C (pl)
CY (1) CY1105766T1 (pl)
DE (1) DE602004002591T9 (pl)
DK (1) DK1624878T3 (pl)
ES (1) ES2274456T3 (pl)
PL (1) PL1624878T3 (pl)
PT (1) PT1624878E (pl)
SI (1) SI1624878T1 (pl)
WO (1) WO2004103377A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034854B2 (en) * 2002-07-12 2015-05-19 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
WO2008144143A1 (en) * 2007-05-14 2008-11-27 Drugtech Corporation Endometriosis treatment
US20100204146A1 (en) * 2007-09-17 2010-08-12 Preglem S.A. Treatment of Oestrogen Dependant Conditions in Pre-menopausal Women
SG195121A1 (en) 2011-06-01 2013-12-30 Estetra S A Process for the production of estetrol intermediates
HUE029252T2 (en) 2011-06-01 2017-02-28 Estetra Sprl Process for the preparation of intermediates of estetrol
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
HUE054589T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Szájban diszpergálódó esztetrol tartalmú tabletta
MD3310333T2 (ro) 2015-06-18 2020-06-30 Estetra Sprl Unitate de dozare orodispersabilă care conține un component estetrol
CN116077454A (zh) 2015-06-18 2023-05-09 埃斯特拉有限责任公司 含雌四醇组分的口腔分散剂量单位
RS61777B1 (sr) 2015-06-18 2021-06-30 Estetra Sprl Oralno-disperzibilna tableta koja sadrži estetrol
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
DK3781171T3 (da) 2018-04-19 2022-05-02 Estetra Srl Sammensætninger og deres anvendelser til lindring af menopause-associerede symptomer
WO2019211322A1 (en) 2018-05-02 2019-11-07 Mithra Pharmaceuticals S.A. Treatment of advanced estrogen receptor positive breast cancer
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2834712A (en) * 1953-05-27 1958-05-13 American Home Prod Urinary estrogen compositions and methods for preparing them
US2753290A (en) * 1953-08-06 1956-07-03 Olin Mathieson Microbiological production of 7-and 15-hydroxy-progesterones
US3440320A (en) * 1964-06-18 1969-04-22 Mortimer D Sackler Chelated suppository and method of using same
US3487152A (en) * 1967-02-07 1969-12-30 Hoffmann La Roche Tablets containing 7 - chloro - 2 - methylamino - 5 - phenyl - 3h - 1,4 - benzodiazepine-4-oxide and conjugated estrogenic substances
US3608075A (en) * 1969-07-28 1971-09-21 American Home Prod Compositions and methods of treating the menopausal syndrome
YU243975A (en) * 1974-10-14 1982-06-30 Schering Ag Process for obtaining 7-hydroxyestradiols
FR2377419A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 11b-substitues 1,3,5 (10) trieniques, leur procede de preparation et leur application comme medicament
US4937238A (en) * 1986-03-04 1990-06-26 The Board Of Regents Of The University Of Nebraska Prevention of mammary carcinoma
US4762717A (en) * 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5270172A (en) * 1991-04-26 1993-12-14 Dekk-Tek, Inc. Method to predict tumor response to therapy
US5468736A (en) * 1993-02-25 1995-11-21 The Medical College Of Hampton Road Hormone replacement therapy
US5811416A (en) * 1994-06-06 1998-09-22 Board Of Regents The University Of Texas System Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US6613757B1 (en) * 1994-09-22 2003-09-02 Board Of Regents, The University Of Texas System Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
US5672609A (en) * 1996-07-18 1997-09-30 Eli Lilly And Company Pyridine compounds, intermediates compositions and methods of use
US6170058B1 (en) * 1997-12-23 2001-01-02 Arcot Systems, Inc. Method and apparatus for cryptographically camouflaged cryptographic key storage, certification and use
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US6291456B1 (en) * 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
GB0005257D0 (en) * 2000-03-03 2000-04-26 Pharmacia & Upjohn Spa Breast cancer hormonal therapy
RU2180570C1 (ru) * 2000-09-25 2002-03-20 Писаревский Юрий Леонидович Способ лечения болевого синдрома при дисфункциях височно-нижнечелюстного сустава у женщин
US6790979B2 (en) * 2002-04-17 2004-09-14 University Of North Carolina At Chapel Hill Curcumin analogues and uses thereof

Also Published As

Publication number Publication date
CY1105766T1 (el) 2011-02-02
EP1624878A1 (en) 2006-02-15
PT1624878E (pt) 2007-01-31
CN1816340A (zh) 2006-08-09
ES2274456T3 (es) 2007-05-16
DE602004002591T2 (de) 2007-08-09
WO2004103377A1 (en) 2004-12-02
CA2526338A1 (en) 2004-12-02
CA2526338C (en) 2012-09-25
CN100431545C (zh) 2008-11-12
DE602004002591T9 (de) 2008-01-03
ATE340580T1 (de) 2006-10-15
SI1624878T1 (sl) 2007-02-28
DK1624878T3 (da) 2007-01-08
EP1624878B1 (en) 2006-09-27
US20060276414A1 (en) 2006-12-07
DE602004002591D1 (de) 2006-11-09

Similar Documents

Publication Publication Date Title
SI1624878T1 (sl) Uporaba sestavkov, ki obsegajo estrogensko komponento, za zdravljenje in preprecevanje muskuloskeletne bolecine
WO2002094275A8 (en) Use of estrogen compounds to increase libido in women
DK1446128T3 (da) Anvendelse af östrogenforbindelser i kombination med progestogenforbindelser i hormonsubstitutionsbehandling
SG155967A1 (en) Hcv ns3-ns4a protease inhibition
HUP0203304A2 (hu) Prosztatarák megelőzésére szolgáló kemoterápiás módszer és készítmény
DK0462189T3 (da) Kombinationsterapi til behandling af østrogenfølsomme sygdomme
CA2162260A1 (en) Methods and formulations for use in treating oophorectomized women
CA2407100A1 (en) 1-aroyl-piperidinyl benzamidines
WO2008085038A3 (en) Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2004043374A3 (en) Methods and compositions for treating cancer using proteasome inhibitors
NO20080150L (no) Inhibitorer av AKT-aktivitet
WO2004006936A8 (en) Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
GEP20135754B (en) Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1
NZ609344A (en) Method for treatment of diarrhea-predominant irritable bowel syndrome
BRPI0516243C1 (pt) uso de um precursor de esteróide sexual selecionado do grupo que consiste em dehidroepiandrosterona, sulfato de dehidroepiandrosterona, androst-5-eno-3b,17b-diol e 4-androsten-3,17-diona, uso do referido precursor em 5 associação com um modulador de receptor de estrogênio seletivo para proteção uterina e da glândula mamária contra câncer, composição farmacêutica e kit
UA92348C2 (en) 17b-HSD1 AND STS INHIBITORS
IL184116A0 (en) Use of thiazolidinone derivatives as antiangiogenic agents
GB2400859A (en) A fuel additive compositions for stabilising blends of ethanol and a hydrocarbon
BRPI0412118A (pt) métodos para melhorar a absorção de aminoácidos, para reduzir a absorção da glicose plasmática, e para prevenir, inibir ou aliviar uma condição de elevado teor de glicose em um vertebrado, e, uso de akg, derivados ou metabólitos de akg, análogos de akg, ou misturas destes
Nishino et al. Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1, 4-diene-3, 17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors
BR9807767A (pt) Composição para o tratamento ou prevenção de câncer da pr;ostata, e uso de um composto, e, uso de n- [ 1 - metil - 1 - ( 4 - metoxifenil ) etil ] - 3 - oxo - 4 - aza - 5 - alfa-androst - 1 - eno - 17 - beta-carboxamida.
BRPI0405842A (pt) composição farmacêutica estabilizada de composto flúor-éter para uso anestésico. método para estabilizar um composto flúor-éter. uso de agente estabilizante para impedir a degradação de composto flúor éter